Global Health Emergency: The Bundibugyo Ebola Outbreak in DRC and Uganda
A severe outbreak of Ebola caused by the rare Bundibugyo ebolavirus strain is spreading across the Democratic Republic of the Congo (DRC) and Uganda. Because there are currently no approved vaccines or therapeutics specifically licensed for this species of Ebola, the World Health Organization (WHO) declared the outbreak a Public Health Emergency of International Concern (PHEIC) on May 17, 2026.
Following a major visit to the outbreak's epicentre in Ituri province, WHO Director-General Dr. Tedros Adhanom Ghebreyesus delivered a comprehensive update on June 3, 2026. He revealed that while the outbreak had a "big head start," coordinated containment efforts are beginning to catch up. Notably, health officials drastically downsized the official case counts on June 2 and 3, 2026, from nearly 1,000 cases to 344 confirmed cases (including 60 deaths) in the DRC, 15 confirmed cases (including 1 death) in Uganda, and 116 remaining suspected cases. This dramatic reduction was the result of clearing a massive testing backlog rather than a decline in transmission.
Technical Challenges & Containment Hurdles
Key operational challenges continue to hinder the response on the ground:
- Low Contact Tracing Rate: Only about 45% of contacts are currently being followed up, far below the target of 90% required to halt transmission. This effort is severely obstructed by regional insecurity, community displacement, and highly mobile populations.
- Community Mistrust: Dr. Tedros emphasized that some local community leaders still do not believe the virus is real, presenting a significant barrier to isolation and treatment efforts.
- Diagnostic Backlogs: Health officials are working to scale up and decentralize laboratory and diagnostic capabilities in priority locations (including Mongbwalu, Beni, Aru, Nyakunde, and Tchomia) to reduce delays in case confirmation.
Prioritizing Experimental Countermeasures
On May 28, 2026, a WHO expert panel convened to identify and prioritize candidate therapeutics and vaccines to test in clinical trials:
- For Treatment: The panel recommended prioritizing three candidate therapeutics for clinical field trials among confirmed cases: the monoclonal antibodies MBP134 and Maftivimab, and the broad-spectrum antiviral remdesivir.
- For Prevention (Post-Exposure Prophylaxis): The oral antiviral obeldesivir (a prodrug of remdesivir) is prioritized for contacts of confirmed cases to prevent them from developing the disease.
- Vaccine Candidates: The single-dose rVSV Bundibugyo vaccine (developed by the International AIDS Vaccine Initiative, or IAVI) is considered the most promising candidate, though it will require 7 to 9 months before it is ready for clinical trials. Another candidate, ChAdOx1 Bundibugyo (developed by Oxford University and the Serum Institute of India), could be ready in 2 to 3 months but still requires additional animal data. The licensed vaccine Ervebo (used for Zaire ebolavirus) is not licensed for Bundibugyo, and its cross-protection remains limited and inconclusive.